Progressive supranuclear palsy (PSP) is a sporadic tauopathy with unknown cause. The H1 tau haplotype is implicated in its etiology;however, it is also present in 60% of normal controls. This, coupled with late symptom onset, indicates that genetics alone does not cause PSP. Support for the environmental factor hypothesis stems from animal models and the observed association between PSP and exposure to mitochondrial complex I inhibitors (i.e., acetogenins), which are neurotoxic to dopaminergic neurons. Impaired metabolism in PSP mitochondria and oxidative injury in affected brain areas also support this hypothesis. Hence, genes and environment may both play a role either alone or through their interactions. This application will determine: 1) if there is an association between PSP and the HI/HI genotype, specific HI sub-haplotypes, alpha-synuclein polymorphisms or parkin gene deficits, or if there are gene-gene interactions;2) if there is an association between PSP occupational and/or environmental chemical exposures functionally or structurally similar to rotenone/acetogenins;and 3) if hypertension or traumatic brain injury prior to symptom-onset is associated with PSP. To disentangle the complex etiology of PSP, this case-control multicenter study involves 500 PSP cases, 500 age/gender matched primary controls, and 500 secondary controls for genetic confirmation. Previous case-control studies have been inconclusive because of limitations in size, scope, or structure. This is the first adequately powered series of PSP cases with matched controls that has the necessary infrastructure to address our hypotheses and explore gene-environmental interactions. As a result, it will help resolve controversies concerning the cause(s) of PSP and will stimulate new avenues of pathogenesis research and prophylactic therapies. Understanding the etiology of PSP may also help explain the causes of other tauopathies such as Alzheimer's disease. This multidisciplinary team of movement disorder specialists, epidemiologists, geneticists, biostatisticians, industrial hygienist and toxicologist is well suited to unravel the complex etiology of PSP. The use of the NINDS cell repository for genetic banking will also allow DNA sample sharing with other investigators.
| Shoeibi, Ali; Litvan, Irene (2018) Prominent tongue and jaw tremor in a patient with probable Progressive Supranuclear Palsy. Mov Disord Clin Pract 5:99-100 |
| Park, Hee Kyung; Ilango, Sindana; Charriez, Christina M et al. (2018) Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Mov Disord 33:468-472 |
| Kelley, Kristen D; Peavy, Guerry; Edland, Steven et al. (2017) The Role of Stress as a Risk Factor for Progressive Supranuclear Palsy. J Parkinsons Dis 7:377-383 |
| Gerstenecker, Adam; Roberson, Erik D; Schellenberg, Gerard D et al. (2017) Genetic influences on cognition in progressive supranuclear palsy. Mov Disord 32:1764-1771 |
| Litvan, Irene; Lees, Peter S J; Cunningham, Christopher R et al. (2016) Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. Mov Disord 31:644-52 |
| Brody, David M; Litvan, Irene; Warner, Steve et al. (2016) Relationship between uric acid levels and progressive supranuclear palsy. Mov Disord 31:663-7 |
| Geurtsen, Gert J; Hoogland, Jeroen; Goldman, Jennifer G et al. (2014) Parkinson's disease mild cognitive impairment: application and validation of the criteria. J Parkinsons Dis 4:131-7 |
| Grijalvo-Perez, Ana M; Litvan, Irene (2014) Corticobasal degeneration. Semin Neurol 34:160-73 |
| Tolosa, Eduardo; Litvan, Irene; Höglinger, Günter U et al. (2014) A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 29:470-8 |
| Burn, David; Weintraub, Daniel; Ravina, Bernard et al. (2014) Cognition in movement disorders: where can we hope to be in ten years? Mov Disord 29:704-11 |
Showing the most recent 10 out of 36 publications
